Reuters logo
BRIEF-FDA grants orphan drug designation to Boehringer Ingelheim's drug for treatment of myelodysplastic syndromes
March 9, 2017 / 1:57 PM / 6 months ago

BRIEF-FDA grants orphan drug designation to Boehringer Ingelheim's drug for treatment of myelodysplastic syndromes

March 9 (Reuters) -

* FDA grants orphan drug designation to boehringer ingelheim’s investigational anti-cd33 monoclonal antibody bi 836858 for treatment of myelodysplastic syndromes

* FDA grants orphan drug designation to boehringer ingelheim’s investigational anti-cd33 monoclonal antibody bi 836858 for treatment of myelodysplastic syndromes Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below